Back HIV/AIDS HIV/AIDS Topics HIV Treatment

HIV Medical Providers Call for Fair Drug Pricing to Expand Access to Treatment

Practitioners from the American Academy of HIV Medicine (AAHIVM) and the HIV Medicine Association (HIVMA) delivered a joint statement to pharmaceutical company executives this week, asking the industry to reconsider its pricing for antiretroviral drugs so that more people in the U.S. and worldwide are able to access treatment. alt

Read more:

Liver Toxicity Uncommon with Modern Antiretroviral Drugs, but Higher Risk for HIV/HCV Coinfected

Recently approved antiretroviral drugs are generally well-tolerated and seldom cause serious liver enzyme elevations, although protease inhibitors are somewhat more likely to do so, researchers reported in the November 28, 2012, advance online edition of AIDS. People with HIV/HCV coinfection are more likely to experience liver toxicity, however, and early hepatitis C treatment may improve the tolerability of HIV therapy.alt

Read more:

HIV11: Stribild Matches Efficacy and Tolerability of Atripla or Boosted Atazanavir at 96 Weeks

The Stribild single-tablet-regimen -- formerly dubbed the Quad -- demonstrated "robust and durable" efficacy and continued to be well-tolerated through 96 weeks, according to findings from 2 studies presented at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this month in Glasgow. alt

Read more:

HIV11: New Studies Challenge Evidence of Reduced Abacavir Potency When Viral Load Is High

An analysis of 2 studies of the new HIV integrase inhibitor dolutegravir presented at the 11th International Congress on Drug Therapy in HIV Infection this month in Glasgow had the incidental effect of bringing into question evidence from a previous study suggesting that the nucleoside reverse transcriptase inhibitor abacavir (Ziagen, also in the Epzicom or Kivexa coformulation) was less potent in people starting HIV therapy with high viral loads than another NRTI drug, tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild coformulations). alt

Read more:

HIV11: UK Study Finds HIV+ Women on Antiretroviral Therapy Have Higher Premature Birth Rate

A review of clinical records from Central Manchester University Hospitals has found more evidence of an increased rate of preterm delivery of babies born to HIV positive women who are taking antiretroviral therapy (ART), according to a study presented at the 11th International Congress on Drug Therapy in HIV Infection in Glasgow this month. alt

Read more:

UNAIDS Reports Progress, PEPFAR Blueprint Looks Towards AIDS-free Generation

The latest global report from UNAIDS, release ahead of World AIDS Day on December 1, highlights progress in stemming the epidemic, including lower rates of new infection in many countries and a growing proportion of HIV positive people on antiretroviral treatment. Continued progress requires adequate funding, however. To that end, U.S. Secretary of State Hillary Clinton this week released a "Blueprint" detailing recent advances and future plans for achieving a generation free from AIDS.alt

Read more:

HIV11: Life Expectancy in Older People with HIV Could Exceed the Average - As Long As ART Keeps Working

The latest forecasts of life expectancy in people with HIV in the U.K., based on mortality data from the UK Collaborative HIV Cohort (UK CHIC) study, show that the average life expectancy of people on antiretroviral therapy (ART) with a CD4 count over 350 cells/mm3 is now very close to the national average, the 11th International Congress on Drug Therapy in HIV Infection in Glasgow heard last week. alt

Read more: